Abstract:Background: The I-SPY 2 trial is a national-wide, multi-institutional clinical trial designed to evaluate multiple new therapeutic drugs for high-risk breast cancer. Previous studies suggest that pathological complete response (pCR) is a viable indicator of long-term outcomes of neoadjuvant chemotherapy for high-risk breast cancer. While pCR can be assessed during surgery after the chemotherapy, early prediction of pCR before the completion of the chemotherapy may facilitate personalized treatment management to achieve an improved outcome. Notably, the acquisition of dynamic contrast-enhanced magnetic resonance (DCEMR) images at multiple time points during the I-SPY 2 trial opens up the possibility of achieving early pCR prediction. Purpose: In this study, we investigated the feasibility of the early prediction of pCR to neoadjuvant chemotherapy using multi-time point DCEMR images and clinical data acquired in the I-SPY2 trial. The prediction uncertainty was also quantified to allow physicians to make patient-specific decisions on treatment plans based on the level of associated uncertainty. Methods: The dataset used in our study included 624 patients with DCEMR images acquired at 3 time points before the completion of the chemotherapy: pretreatment (T0), after 3 cycles of treatment (T1), and after 12 cycles of treatment (T2). A convolutional long short-term memory (LSTM) network-based deep learning model, which integrated multi-time point deep image representations with clinical data, including tumor subtypes, was developed to predict pCR. The performance of the model was evaluated via the method of nested 5-fold cross validation. Moreover, we also quantified prediction uncertainty for each patient through test-time augmentation. To investigate the relationship between predictive performance and uncertainty, the area under the receiver operating characteristic curve (AUROC) was assessed on subgroups of patients stratified by the uncertainty score. Results: By integrating clinical data and DCEMR images obtained at three-time points before treatment completion, the AUROC reached 0.833 with a sensitivity of 0.723 and specificity of 0.800. This performance was significantly superior (p < 0.01) to models using only images (AUROC = 0.706) or only clinical data (AUROC = 0.746). After stratifying the patients into eight subgroups based on the uncertainty score, we found that group #1, with the lowest uncertainty, had a superior AUROC of 0.873. The AUROC decreased to 0.637 for group #8, which had the highest uncertainty. Conclusions: The results indicate that our convolutional LSTM network-based deep learning model can be used to predict pCR earlier before the completion of chemotherapy. By combining clinical data and multi-time point deep image representations, our model outperforms models built solely on clinical or image data. Estimating prediction uncertainty may enable physicians to prioritize or disregard predictions based on their associated uncertainties. This approach could potentially enhance the personalization of breast cancer therapy.

Deconvolution-Based Pharmacokinetic Analysis to Improve the Prediction of Pathological Information of Breast Cancer

Efficient estimation of pharmacokinetic parameters from breast dynamic contrast-enhanced MRI based on a convolutional neural network for predicting molecular subtypes

Radiomic Analysis of Pharmacokinetic Heterogeneity Within Tumor Based on the Unsupervised Decomposition of Dynamic Contrast-Enhanced MRI for Predicting Histological Characteristics of Breast Cancer

Radiomic Features of Pk-DCE MRI Parameters Based on the Extensive Tofts Model in Application of Breast Cancer

Normalizing Flow-Based Distribution Estimation of Pharmacokinetic Parameters in Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

A Clinically Feasible Method to Estimate Pharmacokinetic Parameters in Breast Cancer

Prediction of Breast Cancer Neoadjuvant Chemotherapy Based on Dynamic Enhanced Mode Analysis of Longitudinal Time Images

Predicting Pathological Response after Neoadjuvant Chemotherapy of Breast Cancer Using Pharmacokinetic Histogram Features on Dynamic Contrast-Enhanced Magnetic Resonance Imaging

DCE-MRI Based Analysis of Intratumor Heterogeneity by Decomposing Method for Prediction of HER2 Status in Breast Cancer.

Exploring the Inter-voxel Information in Pharmacokinetic Maps for Cervical Carcinoma Prediction

Radiomics Based On Images Of Pk-Dce Mri To Diagnose Breast Lesions And Predict Molecular Phenotype Of Breast Cancer: Comparison To Quantitative Values Of Pk-Dce Mri

Using Multiparametric MRI with Optimized Synthetic Correlated Diffusion Imaging to Enhance Breast Cancer Pathologic Complete Response Prediction

Machine Learning Approaches to Radiogenomics of Breast Cancer using Low-Dose Perfusion Computed Tomography: Predicting Prognostic Biomarkers and Molecular Subtypes

Quantitative diffusion weighted imaging parameters in tumor and peritumoral stroma for prediction of molecular subtypes in breast cancer

Pharmacokinetic parameters and radiomics model based on dynamic contrast enhanced MRI for the preoperative prediction of sentinel lymph node metastasis in breast cancer

Deep learning prediction of pathological complete response, residual cancer burden, and progression-free survival in breast cancer patients

Decoupling convolution network for characterizing the metastatic lymph nodes of breast cancer patients

Deep learning-based predictive model for pathological complete response to neoadjuvant chemotherapy in breast cancer from biopsy pathological images: a multicenter study

Image-Based Ultrasomics Classifiers: A Potential Method to Noninvasively Predict the Proliferation-Related Biomarker Ki67

Prediction of pathological complete response to chemotherapy for breast cancer using deep neural network with uncertainty quantification

Temporo-Spatial Collaborative Filtering for Parameter Estimation in Noisy DCE-MRI Sequences: Application to Breast Cancer Chemotherapy Response